N
d03180
|
74
|
5/5/2000
|
ritonavir
|
Norvir
|
1
|
Protease Inhibitor
|
N
|
d03984
|
28
|
7/14/2000
|
rosuvastatin
|
Crestor
|
0
|
Antilipemic Agent
|
N
|
d04851
|
149
|
4/27/2006
|
saguinavir
|
Fortovase, SQV
|
1
|
Protease Inhibitor
|
N
|
d03860
|
37
|
7/14/2000
|
sertraline
|
Zoloft
|
0
|
Antidepressant
|
N
|
d00880
|
72
|
5/5/2000
|
spironolactone
|
(generic only)
|
0
|
Antihypertensive
|
N
|
d00373
|
128
|
2/28/2006
|
stavudine
|
Zerit, d4T
|
1
|
Anti-retroviral NRTI
|
N
|
d03773
|
24
|
11/1/1994
|
sulfadiazine
|
Sulfadiazine
|
0
|
Toxoplasmosis
|
N
|
d00118
|
38
|
7/14/2000
|
tenofovir disoproxil fumarate
|
Viread
|
1
|
Anti-retroviral NRTI
|
N
|
d04774
|
85
|
1/1/2002
|
testosterone transdermal
|
Androderm, Androgel, Testim
|
0
|
Wasting
|
N
|
d00558
|
41
|
7/14/2000
|
thalidomide
|
Thalomid
|
0
|
Wasting
|
N
|
d04331
|
57
|
2/1/1999
|
tipranavir
|
Aptivus
|
1
|
Protease Inhibitor
|
N
|
d05538
|
119
|
9/27/2005
|
TMP-SMX
|
Bactrim, Septra, Septra DS
|
0
|
PCP Prophylaxis
|
N
|
d00124
|
18
|
5/1/1992
|
trazadone HCL
|
Desyrel, Desyrel Dividose
|
0
|
Antidepressant
|
N
|
d00395
|
80
|
|
triamterene
|
(generic only)
|
0
|
Antihypertensive
|
N
|
d00396
|
125
|
2/28/2006
|
trimethoprim
|
Proloprim, Trimpex
|
0
|
Antibiotics
|
N
|
d00123
|
100
|
12/1/2003
|
triphasic ethestradiol-norgestimate
|
Tri-Sprintec 28
|
0
|
Contraceptive
|
N
|
d03781
|
140
|
2/28/2006
|
valacyclovir
|
Valtrex
|
0
|
Antiviral
|
N
|
d03838
|
45
|
7/14/2000
|
valganciclovir hydrochloride
|
Valcyte
|
0
|
Antiviral
|
N
|
d04755
|
84
|
|
venlafaxine HCL
|
Effexor XR
|
0
|
Antidepressant
|
N
|
d03181
|
116
|
8/1/2004
|
verapamil
|
(generic only)
|
0
|
Antihypertensive
|
N
|
d00048
|
133
|
2/28/2006
|
zalcitabine
|
Hivid, ddC
|
1
|
Anti-retroviral NRTI
|
N
|
d00127
|
19
|
1/1/1993
|
zidovudine
|
Retrovir, AZT
|
1
|
Anti-retroviral NRTI
|
N
|
d00034
|
01
|
1/1/1992
|
zidovudine-lamivudine
|
Combivir
|
2
|
Anti-retroviral NRTI
|
N
|
d04219
|
33
|
7/14/2000
|
Carbamazepine
|
Tegretol, & XR
|
|
anticonvulsant N
|
N
|
d00058
|
154
|
10/26/06
|
* Y Indicates Prior Authorization Required
NOTE: Peginterferon alfa (including 2b and 2a) and ribavirin covered in combination, and only for treatment of HCV infection in HIV co-infected clients.
The following is a list of covered injectables:
Covered Injectable Products
|
HSN 006071
|
Ciprofloxacin (Cipro i.v.)
|
HSN 006072
|
Ciprofloxacin (Cipro i.v.)
|
HSN 007802
|
Fluconazole (Diflucan)
|
HSN 009792
|
Fluconazole (Diflucan)
|
HSN 004869
|
Fluconazole (Diflucan)
|
HSN 004182
|
Acyclovir (Zovirax)
|
HSN 010893
|
Ampho B C-S (Amphotec)
|
HSN 004128
|
Amphotericin-B (Fungisone)
|
HSN 010219
|
Amphotericin-B Lipid Complex (Abelcet)
|
HSN 012800
|
Amphotericin-B Liposome (Ambisome)
|
HSN 006334
|
Azithromycin (Zithromax)
|
HSN 011506
|
Cidofovir (Vistide)
|
HSN 004045
|
Clindamycin (Cleocin)
|
HSN 004704
|
Clindamycin (Cleocin)
|
HSN 010804
|
Daunorubicin Citrate Liposomal (DaunoXorne)
|
HSN 004013
|
Doxycyline (Vibramycin)
|
HSN 025044
|
Enfuvirtide (Fuzeon)
|
HSN 004553
|
Epoetin Alpha (Epogen, Procrit)
|
HSN 006070
|
Filgrastim (Neupogen)
|
HSN 001624
|
Fluphenazine (Prolixin, generics)
|
HSN 001626
|
Fluphenazine (Prolixin, generics)
|
HSN 013221
|
Foscarnet (Foscavir)
|
HSN 001660
|
Haloperidol (Haldol)
|
HSN 001661
|
Haloperidol (Haldol)
|
HSN 001608
|
Hydroxizine (Atarax, Vistaril)
|
HSN 001063
|
Leucovorin (Wellcovorin, generics)
|
HSN 004157
|
Metronidazole (Flagyl)
|
HSN 001413
|
Nandrolone (Nadrolone)
|
HSN 002826
|
Octreotide (Sandostatin)
|
HSN 024035
|
Peginterferon alfa 2a (Pegasys)
|
HSN 021367
|
Peginterferon alfa 2b (Peg-Intron)
|
HSN 009599
|
Pentamidine (Pentam, NebuPent
|
HSN 001628
|
Prochloperazine (Compazine)
|
HSN 004040
|
Rifampin (Rifadin, Rimactane)
|
HSN 001400
|
Testosterone injection (Depo-Testosterone)
|
HSN 001401
|
Testosterone injection (Delatestryl)
|
Maintenance Drug List
The MADAP maintenance drug list = antiretroviral therapies (NNRTIs, NRTIs, PIs, Fusion Inhibitors).
Prior Authorization
There are three places providers can obtain a prior authorization for the MADAP program: ACS, MADAP and SmartPA. Below will outline which entity gives the Prior Authorization for which category of drug.
PA Drug List
-
Drug
|
Performed by
|
HSN 025044
|
Enfuvirtie (Fuzeon)
|
MADAP
|
HSN 004553
|
Epoetin Alpha (Epogen, Procrit)
|
SmartPA
|
HSN 006070
|
Filgrastim (Neupogen)
|
SmartPA
|
HSN 001412
|
Oxandrolone (Oxandrin)
|
SmartPA
|
HSN 024035
|
Peginterferon alfa 2a (Pegasys)
|
MADAP
|
HSN 021367
|
Peginterferon alfa 2b (Peg-Intron)
|
MADAP
|
HSN 004184
|
Ribavirin (Rebetol, Copegus)
|
MADAP
|
HSN 034927
|
Maraviroc (Selzentry)
|
MADAP
|
The ACS Technical Call Center will handle the following prior authorization requests for MADAP:
EarlyRefill
Quantity
Price per claim limit ≥$2500.00
The ACS PA Call Center will handle the following prior authorization requests for MADAP:
Epoetin Alpha (Epogen, Procrit)
Filgrastim (Neupogen)
Oxandrolone (Oxandrin)
The MADAP staff will handle all other prior authorization requests.
SmartPA
SmartPA is a rules engine driven program that will search existing claim and medical history to evaluate whether or not the recipient has met the set criteria to receive the drug being billed. If the recipient meets criteria then the system generates a Prior Authorization and the claim is paid. If the recipient does not meet criteria, the claim is denied with a SmartPA specific edit advising which criteria was not met.
The following categories are submitted to SmartPA for evaluation:
Epoetin Alpha (Epogen, Procrit)
Filgrastim (Neupogen)
Oxandrolone (Oxandrin)
Copay Only Claim Billing Guidelines
MADAP will allow providers to bill for a copay only claim. In order for the claim to be processed correctly, the following guidelines must be followed.
The system will require claims for COB copay only billing to adhere to the following NCPDP parameters:
NO COB SEGMENT SUBMITTED
OCC = 8
Other Amount Claimed Qualifier = 99
Other Amount Claimed = Amount of copay
Gross Amount Due = Equal Other Amount Claimed/Amount of copay
Other Amount Claimed Submitted must be the entire patient copay as charged by the pharmacy
SECTION X
MARYLAND KIDNEY DISEASE PROGRAM (KDP) SPECIFICS
This section will outline program specific information that is not covered in the beginning of this manual.
Generic Mandatory and Dispense as Written Code Usage
KDP has a generic mandatory program in place that must be followed. When providers submit a claim for a drug that has a generic equivalent and there is no active PA on file or appropriate DAW code, the claim will deny with an NCPDP Reject code ‘22’ – M/I DAW Code.
KDP accepts the following DAW codes:
ACS will ensure that the only valid DAW codes will be 0, 1, 5 and 6:
0 - default, no product selection
1 - Physician request
5 - Brand used as generic
6 – Client Override
KDP allows the use of DAW 6 for medications determined by KDP as follows (pay at EAC):
Duragesic NDCs: 50458003305, 50458003405, 50458003505, 50458003605, 50458003705
Rebetol NDCs: 00085119403, 00085132704, 00085135105, 00085138507
Flonase NDCs: 00173045301
LTC
The KDP system has no LTC recipients and will reject claims submitted with LTC identifiers (NCPDP field 307-C7, Patient Location = 3 – Nursing Home or 4-Long Term/Extended Care) with NCPDP edit 70 and message text: “LTC Claims Not Allowed for Reimbursement”.
Minimum / Maximum Quantities
The KDP program enforces the following Minimum / Maximum quantity limits:
A maximum quantity limit of 350 for the following Immunosuppressive Oral tablets/capsules will be enforced.
Azathioprine
Cyclosporine
Mycophenolate Mofetil (Cellcept)
Sirolimus (Rapamume)
Tacrolimus (Prograf)
HSN = 004523, 004524, 010086, 010012, 020519, 008974; and Route = Oral
There is a max quantity limit of 350 for Immunosuppressants, Oral tablets/capsules.
The max quantity limit for Oxycontin (GSN = 024505, 024506, 025702, 024504, 045129) is 120. Note: This is a per fill quantity limit, not an accumulation limit.
MINIMUM QUANTITY
There is a minimum quantity limit of 100 tablets for Ferrous sulfate 325mg tablets (GSN = 001645, 001646, 017378).
A minimum quantity limit of 480 ml for Ferrous sulfate elixir (220mg/5ml), GSN = 001639) will be applied.
KDP will enforce a minimum quantity limit of 60 tablets for non-legend chewable tablets of any ferrous salt when combined with vitamin C, multivitamins, multivitamins and minerals, or other minerals in the formulation (HIC3 = C3B; and Dosage form = TC).
Date of Rx Written and Date of Service
The system will enforce the following rules regarding the amount of time allowed between Date RX Written and Date of Service:
No greater than 10 days.
Claims greater than this 10 day limit will deny for NCPDP Error Code M4 (Prescription Number/Time Limit Exceeded).
Edit only applies to original prescriptions.
UNIT DOSE
The system will deny claims for unit dose medications with the exception of drugs listed below with error 70 (drug not covered) and message text: “Unit Dose Package Size”.
Unit Dose Drugs Exceptions for Retail Claims (all other U/D will deny with NCPDP 70 – NDC not covered)/ “Unit Dose Package Size”
|
HSN = 000739; and UD
|
Ferrous Sulfate (single ingredient products only)
|
|
GSN = 040910, 040911, 047126; and UD
|
Micardis 20mg, 40mg & 80mg
|
|
GSN = 011964, 011963, 023881, 023882; and UD
|
Cyclosporine 25mg & 100mg caps
|
Includes Gengraf
|
GSN = 031055, 031056; and UD
|
Pepcid RPD
|
|
GSN = 049296, 040887; and UD
|
Prevacid Liquid
|
|
GSN = 009326, 009327; and UD
|
Vancocin HCL
|
|
GSN = 018370; and UD
|
Bactroban Nasal
|
|
Pricing
ACS will ensure the claims reimburse at the following pricing:
Legend Drugs, Schedule V Cough Preps, Enteric Coated Aspirin, Oral Ferrous Sulfate Prods
Payment is lesser of:
U/C -or- Allowable Cost + Dispensing Fee
Allowable Cost is lesser of:
1. IDC,
2. EAC (lesser of): WAC+8%· Direct+8%· Distributors + 8%· AWP - 12%,
3. FUL
Chewable Ferrous Sulfate with Multivitamins
Payment is lesser of:
U/C -or- Allowable Cost + 50% -or- Allowable Cost + Dispensing Fee
Allowable Cost is lesser of:
1. IDC
2. EAC (lesser of): WAC+8% -or- Direct+8% -or- Distributors + 8% -or- AWP - 12%
3. FUL
DAW 1 and 6 Claims
Payment is lesser of:
U/C -or- Allowable Cost + Dispensing Fee
Allowable Cost:
EAC (lesser of): · WAC+8% -or- Direct+8% -or- Distributors + 8% -or- AWP – 12%
Other OTC Drugs (Insulin and Nutritional Supplements)
Payment is lesser of:
U/C -or- Allowable Cost + 50% -or- Allowable Cost + Dispensing Fee
Allowable Cost: AWP
Medical Supplies and Durable Medical Equip (Needles and Syringes)
Payment is lesser of:
U/C -or- Allowable Cost + Dispensing Fee
Allowable Cost: AWP
ACS will ensure that KDP claims do not have copays.
ACS will ensure that claims will reimburse with the following dispensing fee:
Dispensing Fee
Brand Products = $2.69
Generic Products = $3.69
Partial fills – ½ + ½ dispensing fee.
COPAY
KDP recipients do not have a copay.
PRIOR AUTHORIZATIONS
The ACS Technical Call Center will handle the following prior authorization requests for KDP:
Early Refill
Quantity
Price per claim limit ≥ $2500.00
The KDP staff will handle the following prior authorization requests:
Share with your friends: |